Erratum to: Suppression of insulin feedback enhances the efficacy of PI3K inhibitors (Nature, (2018), 560, 7719, (499-503), 10.1038/s41586-018-0343-4);Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

Nature

Volumn 560, Issue 7719, 2018, Pages 499-503

  Hopkins, Benjamin D ^a   Pauli, Chantal ^b,c   Xing, Du ^d   Wang, Diana G ^a   Li, Xiang ^e   Wu, David ^a   Amadiume, Solomon C ^a   Goncalves, Marcus D ^a   Hodakoski, Cindy ^a   Lundquist, Mark R ^a   Bareja, Rohan ^a,c   Ma, Yan ^d   Harris, Emily M ^d   Sboner, Andrea ^a,c   Beltran, Himisha ^a,c   Rubin, Mark A ^c,f   Mukherjee, Siddhartha ^d   Cantley, Lewis C ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d Department of Medicine   (United States)

^e Weill Cornell Medical Center   (United States)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; MTOR PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; EXPERIMENTAL NEOPLASM; FEEDBACK SYSTEM; FEMALE; LETTER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; GLUCOSE BLOOD LEVEL; METABOLISM; NEOPLASM; NUDE MOUSE; PATHOLOGY; PHYSIOLOGICAL FEEDBACK;

MUS;

ANIMALS; BLOOD GLUCOSE; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FEEDBACK, PHYSIOLOGICAL; INSULIN; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 85051695315     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/s41586-018-0506-3     Document Type: Erratum

References (29)

1. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013)
2. Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol. 2, 1565–1573 (2016)
3. Bendell, J. C. et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 30, 282–290 (2012)
4. Juric, D. et al. Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov. 7, 704–715 (2017)
5. Patnaik, A. et al. First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin’s lymphomas. Ann. Oncol. 27, 1928–1940 (2016)
6. − metastatic breast cancer. Clin. Cancer Res. 23, 26–34 (2017)
7. Hopkins, B. D., Goncalves, M. D. & Cantley, L. C. Obesity and cancer mechanisms: cancer metabolism. J. Clin. Oncol. 34, 4277–4283 (2016)
8. Fruman, D. A. et al. The PI3K pathway in human disease. Cell 170, 605–635 (2017)
9. Belardi, V., Gallagher, E. J., Novosyadlyy, R. & LeRoith, D. Insulin and IGFs in obesity-related breast cancer. J. Mammary Gland Biol. Neoplasia 18, 277–289 (2013)
10. Gallagher, E. J. & LeRoith, D. Minireview: IGF, insulin, and cancer. Endocrinology 152, 2546–2551 (2011)
11. Klil-Drori, A. J., Azoulay, L. & Pollak, M. N. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat. Rev. Clin. Oncol. 14, 85–99 (2017)
12. Ma, J. et al. A prospective study of plasma c-peptide and colorectal cancer risk in men. J. Natl. Cancer Inst. 96, 546–553 (2004)
13. Xu, J. et al. Association between markers of glucose metabolism and risk of colorectal cancer. BMJ Open 6, e011430 (2016)
14. Ma, J. et al. Prediagnostic body-mass index, plasma c-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 9, 1039–1047 (2008)
15. Olive, K. P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457–1461 (2009)
16. Pauli, C. et al. Personalized in vitro and in vivo cancer models to guide precision medicine. Cancer Discov. 7, 462–477 (2017)
17. Komoroski, B. et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 85, 513–519 (2009)
18. Demin, O., Jr, Yakovleva, T., Kolobkov, D. & Demin, O. Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model. Front. Pharmacol. 5, 218 (2014)
19. Pollak, M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev. Res. (Phila.) 3, 1060–1065 (2010)
20. Pollak, M. Potential applications for biguanides in oncology. J. Clin. Invest. 123, 3693–3700 (2013)
21. Saura, C. et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin. Cancer Res. 20, 1935–1945 (2014)
22. Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast.1158/2159–8290.CD-11–0336
23. Puchalska, P. & Crawford, P. A. Multi-dimensional roles of ketone bodies in fuel metabolism, signaling, and therapeutics. Cell Metab. 25, 262–284 (2017)
24. Sampaio, L. P. Ketogenic diet for epilepsy treatment. Arq. Neuropsiquiatr. 74, 842–848 (2016)
25. Pauli, C. et al. An emerging role for cytopathology in precision oncology. Cancer Cytopathol. 124, 167–173 (2016)
26. Lee, C., Kim, J. S. & Waldman, T. PTEN gene targeting reveals a radiation-induced size checkpoint in human cancer cells. Cancer Res. 64, 6906–6914 (2004)
27. Pelossof, R. et al. Prediction of potent shRNAs with a sequential classification algorithm. Nat. Biotechnol. 35, 350–353 (2017)
28. Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Reports 5, 1704–1713 (2013)
29. Douris, N. et al. Adaptive changes in amino acid metabolism permit normal longevity in mice consuming a low-carbohydrate ketogenic diet. Biochim. Biophys. Acta 1852, 2056–2065 (2015)